<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39434885</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d).</ArticleTitle><Pagination><StartPage>1468760</StartPage><MedlinePgn>1468760</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1468760</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1468760</ELocationID><Abstract><AbstractText>A monovalent Omicron XBB.1.5 mRNA RBD analogue vaccine, MAFB-7256a (DS-5670d), was newly developed and approved in Japan in the Spring of 2024 for the prevention of COVID-19. However, clinical efficacy data for this vaccine are currently lacking. We previously established the Quantification of Antigen-specific Antibody Sequence (QASAS) method to assess the response to SARS-CoV-2 vaccination at the mRNA level using B-cell receptor (BCR) repertoire assays and the Coronavirus Antibody Database (CoV-AbDab). Here, we used this method to evaluate the immunogenicity of MAFB-7256a. We analyzed repeated blood samples using the QASAS method from three healthy volunteers before and after MAFB-7256a vaccination. BCR response increased rapidly one week post-vaccination and then decreased, as with conventional vaccine. Notably, the matched sequences after MAFB-7256a vaccination specifically bound to the receptor-binding domain (RBD), with no sequences binding to other epitopes. These results validate that MAFB-7256a is an effective vaccine that exclusively induces antibodies specific for the RBD, demonstrating its targeted immunogenic effect.</AbstractText><CopyrightInformation>Copyright © 2024 Ohji, Funakoshi, Yakushijin, Matsutani, Sasaki, Kusakabe, Matsumoto, Koyama, Nagatani, Kurata, Kimbara, Kiyota and Minami.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Ohji</LastName><ForeName>Goh</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Infection Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Funakoshi</LastName><ForeName>Yohei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yakushijin</LastName><ForeName>Kimikazu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsutani</LastName><ForeName>Takaji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Research &amp; Development Department, Repertoire Genesis Inc., Ibaraki, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sasaki</LastName><ForeName>Tomoki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>R&amp;D Department, KAICO Ltd., Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kusakabe</LastName><ForeName>Takahiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory of Insect Genome Science, Graduate School of Bioresource and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsumoto</LastName><ForeName>Sakuya</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koyama</LastName><ForeName>Taiji</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagatani</LastName><ForeName>Yoshiaki</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kurata</LastName><ForeName>Keiji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimbara</LastName><ForeName>Shiro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiyota</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center, Kobe University Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minami</LastName><ForeName>Hironobu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cancer Center, Kobe University Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011947">Receptors, Antigen, B-Cell</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011947" MajorTopicYN="Y">Receptors, Antigen, B-Cell</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell receptor repertoire</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">coronavirus antibody database</Keyword><Keyword MajorTopicYN="N">mRNA RBD vaccine</Keyword><Keyword MajorTopicYN="N">quantification of antigen-specific antibody sequence</Keyword></KeywordList><CoiStatement>KY has received research grants and honoraria from Chugai Pharmaceutical and Pfizer. Author TM was employed by company Repertoire Genesis Inc. and is currently an employee of Maruho Co., Ltd. TS is an employee of KAICO Ltd. NK has received grants from Roche Pharmaceuticals. HM has received research grants and honoraria from Chugai Pharmaceutical. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>4</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39434885</ArticleId><ArticleId IdType="pmc">PMC11491357</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1468760</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and efficacy of the bnt162b2 mrna covid-19 vaccine. N Engl J Med. (2020) 383:2603–15. doi: 10.1056/NEJMoa2034577</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. . Prevention and attenuation of covid-19 with the bnt162b2 and mrna-1273 vaccines. N Engl J Med. (2021) 385:320–9. doi: 10.1056/NEJMoa2107058</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107058</ArticleId><ArticleId IdType="pmc">PMC8262622</ArticleId><ArticleId IdType="pubmed">34192428</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. . Efficacy and safety of the mrna-1273 sars-cov-2 vaccine. N Engl J Med. (2021) 384:403–16. doi: 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CB, Farzan M, Chen B, Choe H. Mechanisms of sars-cov-2 entry into cells. Nat Rev Mol Cell Biol. (2022) 23:3–20. doi: 10.1038/s41580-021-00418-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of sars-cov-2 spike protein: potential antivirus drug development for covid-19. Acta Pharmacol Sin. (2020) 41:1141–9. doi: 10.1038/s41401-020-0485-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41401-020-0485-4</ArticleId><ArticleId IdType="pmc">PMC7396720</ArticleId><ArticleId IdType="pubmed">32747721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W, Zheng Y, Zeng X, He B, Cheng W. Structural biology of sars-cov-2: open the door for novel therapies. Signal Transduct Target Ther. (2022) 7:26. doi: 10.1038/s41392-022-00884-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00884-5</ArticleId><ArticleId IdType="pmc">PMC8793099</ArticleId><ArticleId IdType="pubmed">35087058</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Rao Z. Structural biology of sars-cov-2 and implications for therapeutic development. Nat Rev Microbiol. (2021) 19:685–700. doi: 10.1038/s41579-021-00630-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi Y, Yakushijin K, Ohji G, Matsutani T, Hojo W, Sakai H, et al. . Response to mrna sars-cov-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration. Br J Haematol. (2023) 202:504–16. doi: 10.1111/bjh.18932</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.18932</ArticleId><ArticleId IdType="pubmed">37349876</ArticleId></ArticleIdList></Reference><Reference><Citation>Funakoshi Y, Yakushijin K, Ohji G. Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent omicron xbb.1.5 mrna vaccines. eJHaem. (2024). doi: 10.1002/jha2.932</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jha2.932</ArticleId><ArticleId IdType="pmc">PMC11327733</ArticleId><ArticleId IdType="pubmed">39157599</ArticleId></ArticleIdList></Reference><Reference><Citation>Raybould MIJ, Kovaltsuk A, Marks C, Deane CM. Cov-abdab: the coronavirus antibody database. Bioinformatics. (2021) 37:734–5. doi: 10.1093/bioinformatics/btaa739</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btaa739</ArticleId><ArticleId IdType="pmc">PMC7558925</ArticleId><ArticleId IdType="pubmed">32805021</ArticleId></ArticleIdList></Reference><Reference><Citation>Masuda A, Lee JM, Miyata T, Mon H, Sato K, Oyama K, et al. . Optimization of sars-cov-2 spike protein expression in the silkworm and induction of efficient protective immunity by inoculation with alum adjuvants. Front Immunol. (2021) 12:803647. doi: 10.3389/fimmu.2021.803647</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.803647</ArticleId><ArticleId IdType="pmc">PMC8789674</ArticleId><ArticleId IdType="pubmed">35095889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaura K, Yamashita H, Ayabe H, Shini T, Matsutani T, Suzuki R. Different somatic hypermutation levels among antibody subclasses disclosed by a new next-generation sequencing-based antibody repertoire analysis. Front Immunol. (2017) 8:389. doi: 10.3389/fimmu.2017.00389</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00389</ArticleId><ArticleId IdType="pmc">PMC5413556</ArticleId><ArticleId IdType="pubmed">28515723</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu L, Wittrock KN, Clabaugh GC, Srivastava V, Cho MW. A structural landscape of neutralizing antibodies against sars-cov-2 receptor binding domain. Front Immunol. (2021) 12:647934. doi: 10.3389/fimmu.2021.647934</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.647934</ArticleId><ArticleId IdType="pmc">PMC8113771</ArticleId><ArticleId IdType="pubmed">33995366</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyama K, Eto T, Takazawa K, Shimizu S, Nakayama T, Furihata K, et al. . Ds-5670a, a novel mrna-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: results from a phase 2 clinical study. Vaccine. (2023) 41:5525–34. doi: 10.1016/j.vaccine.2023.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.012</ArticleId><ArticleId IdType="pubmed">37586958</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>